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RESEARCH LETTER
MRI ventilation abnormalities
predict quality-of-life and lung




COPD biomarkers are urgently required for
clinical trials of new therapies. We evaluated the
longitudinal change and relationship of MRI and
CT biomarkers of COPD with St. George's
Respiratory Questionnaire (SGRO) and FEV1
worsening over 30 months. Among imaging
biomarkers, only the longitudinal change in MRI
ventilation defect percent (VDP) was greater in
ever-smoker (n=34/p<0.05) and COPD
(n=48/p<0.0001) subgroups compared with
never-smokers (n=42). Only the longitudinal
change in VDP was correlated with change in
SGRQ (r=0.26/p=0.03), and only baseline VDP
predicted longitudinal change in
SGRQ>minimum clinically important difference
(p=0.047) in mild-to-moderate COPD. These
data strongly support the use of MRI
intermediate endpoints in COPD studies.
Trial Registration Number NCT02723474;
Status: Recruiting.
INTRODUCTION
COPD is a growing public health problem
projected to overwhelm healthcare
systems.1 This is motivating the develop-
ment of new, sensitive COPD biomarkers
that can be used in clinical trials as inter-
mediate study endpoints.
CT biomarkers of emphysema (15th
percentile of the CT density histogram,
HU15%) and airways disease (wall thickness
of airways with 10 mm internal perimeter,
Pi10) have shown promise for providing
prognostic information.2 Although recent
data3 showed that the change in CTemphy-
sema may be used to estimate the efficacy of
therapy in patients with α-1-antitrypsin-
deficiency, thus far none of the currently
developed CT biomarkers have been shown
to reflect changes in outcomes that are
important to patients with COPD. MRI
with inhaled noble gases provide highly
sensitive and unique microstructural and
functional information in COPD.4 MRI
biomarkers of COPD are highly reprodu-
cible,5 are associated with COPD out-
comes6 and detect changes with greater
sensitivity and before disease-related
changes can be detected by CTor FEV1.
7–9
Here we evaluated longitudinal changes
in both CT and MRI measurements of
COPD. Based on previous longitudinal
results,8 10 we hypothesised that 3He MRI
biomarkers would predict quality-of-life
and FEV1 changes in COPD, and that lon-
gitudinal changes in MRI biomarkers
would be correlated with changes in
COPD quality-of-life measures.
METHODS
The Thoracic Imaging Network of Canada
(TINCan) was a single centre, prospective
longitudinal study. Participants aged
40–85 years that were never-smokers,
current/ex-smokers without airflow
Figure 1 MRI ventilation and apparent diffusion coefficient (ADC) maps as well as CT density
masks (<−950 HU in yellow) for representative ever-smoker, mild (GOLD I) and severe (GOLD III)
COPD participants at baseline and follow-up. Ever-smoker (BL/FU): 72/75-year-old female
ex-smoker, FEV1=96/94%pred, FEV1/FVC=88/85%, DLCO=54/62%pred, VDP=5/6%,
ADC=0.34/0.35 cm2/s, LAA950=1/2%, HU15%=−899/−901 HU. Mild COPD (BL/FU): 76/78-year-old
male ex-smoker, FEV1=77/75%pred, FEV1/FVC=57/58/%, DLCO=70/87,VDP=8/14%, ADC=0.30/
0.32 cm2/s, LAA950=2/3%, HU15%=−895/−914 HU. Severe COPD (BL/FU): 67/69-year-old female
ex-smoker, FEV1=37/33%pred, FEV1/FVC=38/39%, DLCO=21/28%pred, VDP=34/44%, ADC=0.51/
0.52 cm2/s, LAA950=33/37%, HU15%=−974/−978 HU. BL, baseline; FU, follow-up; GOLD, Global
Initiative for Chronic Obstructive Pulmonary Disease; VDP, ventilation defect percent.
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limitation (ever-smokers) and COPD were
enrolled. All participants underwent two
visits prospectively planned 2.5 years apart.
Details regarding the study participants, pul-
monary function tests, imaging acquisition/
analysis and statistical analysis are provided
in online supplementary panel S1.
RESULTS
Baseline demographic and clinical character-
istics for all 124 participants (n=42 never-
smokers, n=34 ever-smokers and n=48
patients with COPD of which n=38 were
mild to moderate) are provided in online
supplementary table S1 and described in
online supplementary panel S2. The mean
time between baseline and follow-up for all
participants was 29±5 months.
Figure 1 shows representative baseline
and follow-up MRI ventilation and apparent
diffusion coefficient (ADC) maps as well as
CT density masks for an ever-smoker, and
patients with mild and severe COPD. The
longitudinal changes in imaging biomarkers
are described in online supplementary panel
S3 and summarised in online supplementary
table S2 and figure S1; all COPD subjects
and the mild-to-moderate subgroup were
evaluated separately. The magnitude of
the longitudinal change was greater in
ever-smoker (p<0.05), mild-to-moderate
(p=0.001) and all COPD (p<0.0001) sub-
groups than in never-smokers for ventilation
defect percent (VDP), but not for ADC,
HU15% or Pi10.
The relationship between the longitu-
dinal change in SGRQ and FEV1 with the
change in imaging measurements is shown
in online supplementary table S3. The lon-
gitudinal change in SGRQ was significantly
correlated with the longitudinal change in
VDP (r=0.26, r2=0.09, p=0.03), but not
for ADC, HU15% or Pi10.
Although the magnitude of the SGRQ
change was not significantly greater at
follow-up in any of the subgroups investi-
gated (see online supplementary figure S1),
the longitudinal SGRQ change>minimum
clinically important difference (MCID)
was reported in several COPD participants
(24%). Table 1 and online supplementary
table S4 show the results of multivariate
modelling for baseline imaging predictors
of SGRQ change >MCID, as well as
the annual and accelerated change in
FEV1. In mild-to-moderate COPD, only
baseline VDP significantly predicted the
longitudinal change in SGRQ>MCID
(p=0.047). Both MRI and CT biomarkers
significantly predicted annual (VDP/
p=0.003; ADC/p=0.02; Pi10/p=0.02)
and accelerated FEV1 change (VDP/
p=0.009; ADC/ p=0.004; HU15%/
p=0.01; Pi10/p=0.03).
DISCUSSION
FEV1 is still the most commonly used
endpoint in COPD clinical trials which
often require large sample sizes and
long follow-up times to enable the detec-
tion of significant responses to therapy.
Moreover, in clinical trials using CT,
which may provide a more direct meas-
urement of COPD pathology, there are a
lack of studies showing that currently
developed CT biomarkers reflect changes
in patient-relevant outcomes. This moti-
vated the development of TINCan—the
first prospective study to longitudinally
investigate both functional MRI and CT
biomarkers as predictors of clinical out-
comes in patients with COPD.
As might be expected due to the small
sample size, the change in FEV1 was not
Table 1 Regression models for annual and accelerated FEV1 change and change in SGRQ>MCID
Ever-smoker n=34 Mild-to-moderate COPD n=38 All COPD n=48
Standardised estimate p Value Standardised estimate p Value Standardised estimate p Value
A. Change in SGRQ>MCID
Model 1: VDP −69.28 0.41 0.82 0.047 0.97 0.02
FEV1 −12.28 0.46 0.07 0.89 0.15 0.72
Model 2: ADC 0.56 0.26 1.08 0.07 0.53 0.11
FEV1%pred −0.88 0.32 −0.72 0.14 −0.30 0.35
Model 3: HU15% −0.99 0.11 −2.83 0.06 −1.89 0.01
FEV1%pred −0.87 0.30 0.02 0.97 0.06 0.89
Model 4: Pi10 0.40 0.36 0.03 0.95 −0.13 0.65
FEV1%pred −0.78 0.31 −0.63 0.18 −0.45 0.16
B. Annual change in FEV1
Model 1: VDP −0.03 0.89 −0.58 0.003 −0.56 0.006
FEV1 −0.44 0.17 −0.45 0.04 −0.44 0.04
Model 2: ADC 0.25 0.31 −0.40 0.02 −0.43 0.007
FEV1%pred −0.45 0.14 −0.15 0.44 −0.23 0.16
Model 3: HU15% 0.15 0.47 0.23 0.27 0.32 0.09
FEV1%pred −0.41 0.19 −0.11 0.61 −0.17 0.32
Model 4: Pi10 −0.01 0.95 −0.43 0.02 −0.35 0.03
FEV1%pred −0.45 0.15 −0.19 0.34 −0.17 0.31
C. Change in FEV1>40 mL/year
Model 1: VDP −0.34 0.16 1.26 0.009 0.98 0.007
FEV1 0.42 0.24 0.65 0.11 0.59 0.08
Model 2: ADC −0.15 0.58 1.07 0.004 0.75 0.007
FEV1%pred 0.29 0.39 0.20 0.53 0.17 0.50
Model 3: HU15% −0.45 0.09 −1.12 0.01 −1.12 0.006
FEV1%pred 0.19 0.58 0.19 0.55 0.27 0.31
Model 4: Pi10 0.02 0.91 0.55 0.03 0.38 0.07
FEV1%pred 0.28 0.39 0.05 0.85 0.07 0.76
Models adjusted for age, sex, body mass index, smoking status and pack-years.
ADC, apparent diffusion coefficient; MCID, minimum clinically important difference; VDP, ventilation defect percent.
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significantly different between patient sub-
groups, nor was the change in CT mea-
surements. The finding that the change in
ADC was not significantly different
between subgroups was also not surpris-
ing, and was likely related to the fact that
ADC can only be measured in well-
ventilated lung; this means that lung
regions without inhaled gas (ie, ventilation
defects) cannot report ADC values and
this can drive an inherent bias towards
more normal ADC measurements at
follow-up.
VDP was the only imaging biomarker
in which the longitudinal change was
greater in patients with COPD than never-
smokers. This is consistent with previous
work8 10 and suggests that only MRI ven-
tilation abnormalities differentiated
disease-related worsening from age-related
decline. MRI ventilation abnormalities
and their worsening over time likely
reflect lung regions that trap gas via a
fixed obstruction or have long time con-
stants for filling/emptying. Taken together
with other studies,7–9 our findings suggest
that MRI ventilation abnormalities are
visualised and detected before CT struc-
tural changes—an important observation
that can reduce the size and duration of
COPD clinical trials.
In order for a biomarker to be validated
as an intermediate endpoint, regulatory
authorities require that changes in biomar-
kers correlate with changes in clinical out-
comes. Remarkably, VDP was also the
only imaging biomarker for which the
longitudinal change was correlated with
the longitudinal change in SGRQ. Perhaps
more importantly, in the patients with
mildest COPD, only MRI biomarkers pro-
vided prognostic information and pre-
dicted the longitudinal change in clinically
relevant quality-of-life measures.
A very important limitation in this study
is that only two time points were evalu-
ated. Including a third time point would
add strength to our study and to the
conclusions drawn. Other limitations
of our study are described in online
supplementary panel S4.
The growing burden of COPD and
dearth of new treatments demands aggres-
sive and targeted development of more
sensitive COPD intermediate endpoints.
Our findings show that the change in
MRI ventilation defects over time may
represent a ‘canary in the coal mine’ that
signals future changes in clinical out-
comes, even in mild patients and even
when FEV1 and CT biomarkers cannot
detect these occurrences. As in coal
mining, COPD treatment trials might con-
sider the utility of a ‘canary’ to serve as
an intermediate endpoint.
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